1. Home
  2. Blog
  3. UPSC

Approval of the First Chikungunya Vaccine

Why is it in the news?

  • The world’s first vaccine for chikungunya was approved by the S. Food and Drug Administration (FDA) recently.

More about the Vaccine Development

  • Developed by Valneva, a European vaccine manufacturer, the vaccine is marketed under the brand name Ixchiq is administered as a single-dose injection into the muscle.
  • It contains a live, weakened version of the chikungunya virus and may cause similar symptoms to the disease.
  • It is approved for individuals aged 18 and older who are at increased risk of exposure to the chikungunya virus.
  • The vaccine was granted approval through the Accelerated Approval pathway, which is used for products that address serious or life-threatening conditions based on evidence of effectiveness likely to provide clinical benefit.


About Chikungunya

路聽聽聽聽聽聽 Chikungunya is a viral infection characterized by severe joint pain, fever, impaired mobility, and other symptoms.

路聽聽聽聽聽聽 It is primarily transmitted by Aedes aegypti and Aedes albopictus mosquitoes.

路聽聽聽聽聽聽 Chikungunya is considered an emerging global health threat, prevalent in Africa, Asia, and the Americas.

路聽聽聽聽聽聽 Since 2004, outbreaks of CHIKV have become more frequent and widespread due to viral adaptations.

路聽聽聽聽聽聽 Symptoms include joint pain, swelling, muscle pain, headache, nausea, fatigue, and rash.

路聽聽聽聽聽聽 Severe symptoms and deaths are rare, but the disease is often misdiagnosed as dengue or Zika.


Significance of the Vaccine

  • The FDA’s approval of the chikungunya vaccine addresses an unmet medical need and represents an important advancement in preventing this debilitating disease.
  • The vaccine may help countries where chikungunya is more prevalent, such as Brazil, Paraguay, India (with a high number of suspected cases), and parts of western Africa.
  • It is expected to have a positive impact on public health by reducing the risk and spread of chikungunya.

Leave a Reply

Discover more from AMIGOS IAS

Subscribe now to keep reading and get access to the full archive.

Continue reading